A real-world analysis of second-line treatment option, Gemcitabine plus Anlotinib and anti-PD1, in advanced pancreatic cancer: A critical insight
13 Jun 2025, noon
Publication date: Available online 12 June 2025Source: PancreatologyAuthor(s): Asjad Zahra, ...